A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects
A 6-Month, Randomized, Double-Blind, Placebo And Positive-Controlled Phase 2b Study To Evaluate The Effect Of Various Doses Of CP-945,598 On Weight Loss In Obese Subjects
To evaluate the effect of 6-month administration of CP-945,598 on:
- weight loss and waist circumference,
- blood pressure, cholesterol, glucose
- other biochemical variables like insulin, leptin, ghrelin, adiponectin, PAI 1, TNF-α and hsCRP
- the relationship between the concentration of the drug on the blood and the above parameters
- physical and psychosocial functioning, weight related symptoms, treatment satisfaction, appetite/hunger/satiety/craving and mood, anxiety, anhedonia and depression
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Florida
-
Clearwater, Florida, United States, 33761
- Pfizer Investigational Site
-
Kissimmee, Florida, United States, 34741
- Pfizer Investigational Site
-
Orlando, Florida, United States, 32809
- Pfizer Investigational Site
-
-
Kentucky
-
Lexington, Kentucky, United States, 40509
- Pfizer Investigational Site
-
Louisville, Kentucky, United States, 40213
- Pfizer Investigational Site
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70808
- Pfizer Investigational Site
-
-
Massachusetts
-
Milford, Massachusetts, United States, 01757
- Pfizer Investigational Site
-
-
New York
-
New York, New York, United States, 10021
- Pfizer Investigational Site
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28211
- Pfizer Investigational Site
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Pfizer Investigational Site
-
-
Texas
-
Dallas, Texas, United States, 75231
- Pfizer Investigational Site
-
Dallas, Texas, United States, 75247
- Pfizer Investigational Site
-
San Antonio, Texas, United States, 78229
- Pfizer Investigational Site
-
-
Washington
-
Tacoma, Washington, United States, 98418
- Pfizer Investigational Site
-
Tacoma, Washington, United States, 98403
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and/or female subjects without clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurements, 12 lead ECG and clinical laboratory tests
- Body Mass Index (BMI) ³30 and <40 kg/m2, for subjects with no additional
- co morbidities; BMI ³27 kg/m2 and <40 kg/m2, for subjects with co morbidities [history of essential hypertension and/or dyslipidemia defined as high LDL (³160 mg/dL) or high total cholesterol (³240 mg/dL)];
Exclusion Criteria:
- Subjects with resting sitting systolic blood pressure of 140 mmHg or greater or diastolic blood pressure of 90 mmHg or greater.
- Subjects with type 2 diabetes or fasting blood glucose concentration ³126 mg/dL;
- Subjects with a history of eating disorders like anorexia nervosa or bulimia nervosa
- Subjects on prescription and non-prescription appetite or weight modifying drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Determine the effect of various doses of CP 945,598 on body weight in obese subjects after 24 weeks of dosing
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Evaluate the safety and tolerability of CP 945,598 in a 26 week outpatient setting;; -Explore the effect of CP 945,598 on: waist circumference, PD measurements of selected biochemical variables related to energy deficit and weight loss includ
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- A5351013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.